Moderna Continues mRNA Norovirus “Vaccine” Trials Following Guillain-Barré Case
A first-ever norovirus “vaccine”—another experimental biological product produced by Moderna, Inc., using novel mRNA technology—may be on the horizon even though last month the U.S. Food and Drug Administration (FDA) paused Moderna’s late-stage clinical trial following a report of Guillain-Barré syndrome (GBS), a rare neurological side effect that has also surfaced in its RSV vaccine […]